AN6015 / Adlai Nortye, Xiamen Biotime Biotech - LARVOL DELTA

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025) (PRNewswire) - "Adlai Nortye...announced that it has entered into a Global License Agreement with Xiamen Biotime Biotechnology Co., Ltd. ('Biotime') for several compounds. This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide. According to the terms of the agreement, the total amount of this cooperation will reach hundreds of millions of yuan, including the upfront payments, progress-dependent milestone payments and tiered royalties on sales."

Licensing / partnership • Oncology